Target Name: USP28
NCBI ID: G57646
Review Report on USP28 Target / Biomarker Content of Review Report on USP28 Target / Biomarker
USP28
Other Name(s): ubiquitin thiolesterase 28 | Deubiquitinating enzyme 28 | Ubiquitin thioesterase 28 | Ubiquitin specific peptidase 28, transcript variant 1 | ubiquitin-specific-processing protease 28 | KIAA1515 | deubiquitinating enzyme 28 | USP28 variant 1 | ubiquitin carboxyl-terminal hydrolase 28 variant 1 | Ubiquitin specific protease 28 | Ubiquitin carboxyl-terminal hydrolase 28 | UBP28_HUMAN | Ubiquitin-specific-processing protease 28 | Ubiquitin carboxyl-terminal hydrolase 28 (isoform a) | ubiquitin thioesterase 28 | ubiquitin specific peptidase 28

USP28: A Potential Drug Target and Biomarker

USP28 (ubiquitin thiolesterase 28) is a protein that is expressed in various cell types of the human body, including immune cells, neurons, and cardiac muscle cells. It plays a crucial role in the regulation of protein-protein interactions, which are essential for various cellular processes.USP28 has also been shown to be involved in the development and progression of certain diseases, such as cancer and neurodegenerative disorders. Therefore, targeting USP28 may be a promising strategy for the development of new treatments for these diseases.

Diseases and USP28

USP28 has been shown to be involved in the development and progression of various diseases. One of the most well-studied functions of USP28 is its role in the regulation of protein-protein interactions. USP28 has been shown to play a critical role in the regulation of the interaction between Ubiquitin and target proteins. This interaction is important for the regulation of various cellular processes, including DNA replication, cell division, and cell signaling.

In addition to its role in protein-protein interactions, USP28 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to play a critical role in the regulation of the JAK/STAT signaling pathway, which is involved in the regulation of cellular signaling pathways that are important for the development and progression of many diseases, including cancer.

Furthermore, USP28 has also been shown to be involved in the regulation of cellular apoptosis. Apoptosis is an essential process for the regulation of cellular growth and development, and it is also important for the regulation of cellular stress and stress responses. USP28 has been shown to play a critical role in the regulation of cellular apoptosis, and its dysfunction has been implicated in the development and progression of many diseases, including neurodegenerative disorders.

Targeting USP28

Targeting USP28 may be a promising strategy for the development of new treatments for various diseases. One of the most promising approaches for targeting USP28 is the use of small molecules that can inhibit its function. Small molecules that can inhibit the activity of USP28 have been shown to be effective in a variety of cellular assays, including cell-based assays and in animal models of disease.

Another approach for targeting USP28 is the use of antibodies that can specifically recognize and target its protein. Antibodies that recognize and target USP28 have been shown to be effective in a variety of cellular assays, including cell-based assays and in animal models of disease. These antibodies have the potential to be used in a variety of therapeutic approaches, including cancer immunotherapy and neurodegenerative disorders.

Conclusion

In conclusion, USP28 is a protein that is involved in the regulation of protein-protein interactions, cellular signaling pathways, and cellular apoptosis. Its dysfunction has been implicated in the development and progression of various diseases, including cancer and neurodegenerative disorders. Therefore, targeting USP28 may be a promising strategy for the development of new treatments for these diseases. The use of small molecules or antibodies that can inhibit or specifically recognize and target USP28 have the potential to be effective in a variety of therapeutic approaches. Further research is needed to fully understand the role of USP28 in the development and progression of diseases and to develop effective treatments.

Protein Name: Ubiquitin Specific Peptidase 28

Functions: Deubiquitinase involved in DNA damage response checkpoint and MYC proto-oncogene stability. Involved in DNA damage induced apoptosis by specifically deubiquitinating proteins of the DNA damage pathway such as CLSPN. Also involved in G2 DNA damage checkpoint, by deubiquitinating CLSPN, and preventing its degradation by the anaphase promoting complex/cyclosome (APC/C). In contrast, it does not deubiquitinate PLK1. Specifically deubiquitinates MYC in the nucleoplasm, leading to prevent MYC degradation by the proteasome: acts by specifically interacting with isoform 1 of FBXW7 (FBW7alpha) in the nucleoplasm and counteracting ubiquitination of MYC by the SCF(FBW7) complex. In contrast, it does not interact with isoform 4 of FBXW7 (FBW7gamma) in the nucleolus, allowing MYC degradation and explaining the selective MYC degradation in the nucleolus. Deubiquitinates ZNF304, hence preventing ZNF304 degradation by the proteasome and leading to the activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) in a subset of colorectal cancers (CRC) cells (PubMed:24623306)

The "USP28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2